# Blood Formation, Coagulation, and Thrombosis Agents: Colony Stimulating Factors

## LENGTH OF AUTHORIZATIONS

 Approval based upon diagnosis:

| Diagnosis | Approval Length |
|---|---|
| Acute Myeloid Leukemia (AML) | 14 days or duration of chemotherapy regimen |
| Malignancy at risk for febrile neutropenia or undergoing myeloablative chemotherapy prior to allogeneic or autologous bone marrow transplantation | 14 days or duration of chemotherapy regimen |
| Myeloid Engraftment for bone marrow transplant (BMT) | 30 days |
| Severe, chronic neutropenia with absolute neutrophil count (ANC) of less than 500/mm3 and have symptoms associated with neutropenia (e.g. fever, infections, oropharyngeal ulcers). | 30 days |
| Hematopoietic radiation injury syndrome | 30 days |

## Prior Authorization Criteria

1. Is there any reason the patient cannot be changed to a medication not requiring prior approval?

    Acceptable reasons include:

    - Allergy to medications not requiring prior approval
    - Contraindication to all medications not requiring prior approval
    - History of unacceptable/toxic side effects to medications not requiring prior approval

2. Has the patient failed a therapeutic trial of **14 days** with one preferred medication?
3. Will the medication be used for an approved FDA indication and duration?

## Colony Stimulating Factors

Blood Formation, Coagulation, and Thrombosis Agents: Colony Stimulating Factors

| PREFERRED | NON-PREFERRED |
| :--- | ---: |
| Neupogen PA  | Fulphila |
| Ziextenzo PA | Granix |
|   | Leukine  |
|   | Neulasta |
|   | Nivestym |
|   | Nyvepria |
|   | Udenyca  |
|   | Zarxio   |

### Link to Criteria

[Blood Formation, Coagulation, and Thrombosis Agents: Colony Stimulating Factors](https://pharmacy.medicaid.ohio.gov/sites/default/files/20220415_UPDL_Criteria_FINAL_.pdf#page=10)
